Tag
Interim analysis of a phase 3 trial demonstrates povetacicept’s efficacy in reducing proteinuria and pathological markers in IgA nephropathy, with a favorable safety profile.
Ravulizumab, a terminal complement C5 inhibitor, significantly reduces proteinuria in adults with IgA nephropathy, demonstrating safety and biomarker improvements in phase 2 and 3 trials, highlighting its therapeutic potential.
Proteinuria levels in women with preterm pre-eclampsia correlate strongly with pregnancy latency and maternal adverse outcomes but not perinatal outcomes, providing useful prognostic information comparable to angiogenic biomarkers.
Higher proteinuria in preeclampsia was linked to greater long-term risk of maternal hypertension and chronic kidney disease, with overall increased risk of cardiovascular disease as well.
The Phase 3 VISIONARY trial interim analysis demonstrates that sibeprenlimab, a monoclonal antibody targeting APRIL, significantly reduces proteinuria and pathogenic IgA1 in patients with IgA nephropathy, offering a promising upstream thera
A Phase 2 trial of BI 764198, a selective TRPC6 inhibitor, demonstrates significant proteinuria reduction in patients with focal segmental glomerulosclerosis. This study provides the first clinical evidence for podocyte-targeted therapy, ma
The APPEAR-C3G phase 3 trial demonstrates that oral iptacopan significantly reduces proteinuria and is well tolerated in adults with C3 glomerulopathy, an ultra-rare glomerulonephritis linked to alternative complement pathway overactivation
Recent clinical trials of APRIL-targeted monoclonal antibodies—zigakibart, sibeprenlimab, and telitacicept—demonstrate safety and significant proteinuria reduction in IgA nephropathy and IgA vasculitis nephritis, offering promising disease-
Recent research uncovers a significant correlation between proteinuria and the risk of sudden cardiac arrest in young individuals, emphasizing the need for early detection and intervention.
